MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
Europe contemplates unified drug prices to counter US pressure to spend more. Experts are guarded in their expectations.
Pricing and Market Access
Reformed pharmaceutical regulation across India’s drug landscape
What Ojemda’s JCA reveals about new era of clinical HTA in Europe
Turning AI skeptics into AI advocates through high-integrity data
US patent infringement investigation targets German drug price control measures
CDA data reveals trends on drug approvals and reimbursements in Canada
Healthcare cost inflation is back in the headlines
Japan’s FY26 price revision expands G1 repricing and drives price reduction
